Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,648 recruiting studies in this area right now.
By phase
- Not applicable9,813
- Phase 24,456
- Phase 12,744
- Phase 1/Phase 21,689
- Phase 31,402
- Phase 2/Phase 3281
- Phase 4263
Top conditions
- Breast Cancer1,229
- Cancer660
- Prostate Cancer656
- Colorectal Cancer493
- Lung Cancer426
- Ovarian Cancer341
- Multiple Myeloma330
- Gastric Cancer298
- Acute Myeloid Leukemia293
- Pancreatic Cancer292
- Hepatocellular Carcinoma284
- Solid Tumor258
- Advanced Solid Tumor257
- Cervical Cancer232
- Head and Neck Cancer227
- Endometrial Cancer206
- Advanced Solid Tumors195
- Esophageal Cancer191
Leading sponsors
- M.D. Anderson Cancer Center452
- Fudan University315
- Sun Yat-sen University291
- Memorial Sloan Kettering Cancer Center288
- National Cancer Institute (NCI)287
- Mayo Clinic240
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences151
- City of Hope Medical Center144
- AstraZeneca133
- University Health Network, Toronto125
Where studies are running
- California1,426
- Texas641
- Arizona510
- Florida450
- Alabama420
- New York410
- Massachusetts339
- Maryland330
- New Jersey269
- Pennsylvania240
Recruiting studies20,648 total
- NCT04919382RecruitingPhase 2
Temozolomide plus atezolizumab for advanced small cell lung cancer
This trial studies temozolomide plus atezolizumab in people with metastatic or recurring small cell lung cancer that has already come back or progressed after standard platinum chemotherapy plus immunotherapy. It may help by trying a new combination after prior treatment has stopped working.
Chicago, IllinoisAges 18 years+ - NCT04920032RecruitingPhase 1
Blood test–guided extra treatment for colon cancer recurrence risk
This Phase 1 study uses a blood test called ctDNA to decide whether and how to adjust treatment in people with colon cancer who still have a small amount of disease left after surgery. If your blood test remains positive, the trial aims to reduce recurrence risk by guiding treatment changes.
Orange, CaliforniaAges 18 years+ - NCT04920149RecruitingPhase 2
Mesalamine to help prevent colon cancer in Lynch syndrome
This trial tests whether mesalamine, a medicine used for bowel inflammation, can help prevent colorectal cancer in people with Lynch syndrome who do not currently have cancer. It may help by lowering the chance that new pre-cancer growths form over time.
AalborgAges 30 years+ - NCT04921137RecruitingPhase 4
Testing benefits and side effects of hormone therapy in older breast cancer patients
This study looks at the potential harms and benefits of hormone (endocrine) therapy in people age 70 and older with early-stage, hormone-receptor–positive breast cancer. It may help doctors choose which hormone treatment approach is safest and most helpful for older patients.
Edmonton, AlbertaAges 70 years+ - NCT04920617RecruitingPhase 2
Vaccine plus pembrolizumab, with or without low-dose chemo
This Phase 2 study tests whether a cancer vaccine called DPX-Survivac, along with pembrolizumab (an immune medicine), can help shrink diffuse large B-cell lymphoma (DLBCL) that has come back or not responded. It also looks at whether adding intermittent low-dose cyclophosphamide (a low-dose chemotherapy) improves results.
Fountain Valley, CaliforniaAges 18 years+ - NCT04921527RecruitingPhase 3
Chiauranib with weekly paclitaxel for tough ovarian cancer
This Phase 3 trial tests whether chiauranib combined with weekly paclitaxel can shrink recurrent ovarian, fallopian tube, or primary peritoneal cancer that did not respond to platinum chemotherapy. It is designed for people who have limited treatment options after platinum-resistant or platinum-refractory disease.
Shanghai, ChinaAges 18–70 - NCT04923178Recruiting
Natural history study of bladder and other genital cancers
This study follows people with urothelial cancer and certain rare genital (genitourinary) cancers over time to learn how these diseases progress. It may help researchers understand patterns of symptoms and outcomes, even if it is not a drug trial.
Bethesda, MarylandAges 18 years+ - NCT04921917Recruiting
Exercise during treatment for soft tissue sarcoma in an arm or leg
This trial studies whether adding an exercise program helps people with soft tissue sarcoma in an arm or leg during a planned treatment course. The treatment they look at is radiation before surgery, then surgery to remove the tumor, and they want to see how exercise affects outcomes and recovery.
Durham, North CarolinaAges 18–85 - NCT04922567RecruitingPhase 2
Lenalidomide plus CHOP versus CHOP for untreated PTCL
This Phase 2 trial compares two chemotherapy approaches—adding lenalidomide to CHOP versus CHOP alone—for people with untreated peripheral T-cell lymphoma (PTCL). The goal is to see if the added medicine improves response and safety.
Hangzhou, ZhejiangAges 18–75 - NCT04923126RecruitingPhase 1/Phase 2
Mirdametinib for children with low-grade brain tumors
This Phase 1/2 study tests mirdametinib, a targeted medicine, in children and young adults with low-grade glioma (a slower-growing brain tumor). It aims to find the best dose and see how well the treatment works, especially for tumors with certain “MAPK pathway” changes.
Memphis, TennesseeAges 2–24 - NCT04925154Recruiting
Study of decision-making for rectal cancer treatment
This study asks people newly diagnosed with rectal cancer about how they choose between treatment benefits and quality of life. It uses questionnaires to understand what tradeoffs matter to patients so care discussions can be improved.
Montreal, QuebecAges 18 years+ - NCT04924075RecruitingPhase 2
Belzutifan for cancers linked to VHL or HIF-2α changes
This Phase 2 study tests belzutifan (MK-6482) to treat certain advanced cancers caused by specific gene or disease changes, including VHL-related tumors and HIF-2α related tumors. It may help shrink tumors or slow their growth in people whose cancer matches these genetic or disease patterns.
Los Angeles, CaliforniaAges 12 years+ - NCT04925609RecruitingPhase 1/Phase 2
Brigatinib for young people with ALK-positive cancer
This trial tests brigatinib, a targeted pill medicine, in children and young adults with ALK-positive cancers (including ALCL and IMT, plus some other solid tumors). It’s designed to see how well it works and what side effects it causes in people whose tumors have a specific ALK change.
ParisAges 1–25 - NCT04925856Recruiting
Monitoring the immune system during breast cancer drug treatment
This study looks at how your immune system changes while you receive standard breast cancer treatments. The researchers measure immune-related signals during your treatment to better understand what may be happening in triple-negative or certain hormone-receptor breast cancers.
BesançonAges 18–85 - NCT04926584Recruiting
Immunotherapy for advanced or limited-spread lung cancer
This trial tests whether starting immunotherapy can help people with newly diagnosed advanced or limited-spread non-small cell lung cancer that cannot be fully cured with standard local treatments. It may offer a new treatment approach when surgery or definitive chemoradiation isn’t a good option.
Esslingen am NeckarAges 18 years+ - NCT04927416RecruitingPhase 2
Ga-DOTATATE PET/CT scan in metastatic thyroid cancer
This study tests whether a specific special scan (68-Gallium DOTATATE PET/CT) can help doctors better see where thyroid cancer has spread. It focuses on certain types of thyroid cancer and compares how well the scan images metastases.
Bethesda, MarylandAges 18–98 - NCT04927897Recruiting
Testing where to aim extra rectal radiation before surgery
This trial tests the best place to target an “extra boost” of radiation inside the rectum for certain rectal cancer patients. It may help guide more precise treatment planning before they have total mesorectal excision (TME) surgery.
Maastricht, LimburgAges 18 years+ - NCT04928677RecruitingPhase 1
Codrituzumab for children and young adults with GPC3-positive solid tumors
This Phase 1 study tests codrituzumab, an antibody medicine, in children and young adults whose solid tumor has come back or did not respond to standard treatment. It’s designed to see how the treatment works and how safe it is, especially for tumors that test positive for GPC3.
Los Angeles, CaliforniaAges 1–21 - NCT04929223RecruitingPhase 1
Targeted drug study for metastatic colon or rectal cancer
This Phase 1 study tests targeted cancer treatments in people with metastatic colorectal cancer, using genetic “biomarker” results to match you to the right treatment group. It focuses first on safety, and also looks for early signs the treatment may work in specific tumor subgroups.
Birmingham, AlabamaAges 18 years+ - NCT04929769Recruiting
Surgery trial for early cervical cancer using radical hysterectomy
This trial studies whether a radical hysterectomy—performed either through laparoscopy or an open abdominal operation—works best for certain early-stage cervical cancers. It may help improve cancer control and guide how doctors choose the best surgical approach for your stage.
Shanghai, Shanghai MunicipalityAges 21–70 - NCT04929912Recruiting
Registry for people treated with electroporation for cancer
This study is a real-world registry that collects information about people who have already received cancer treatment using electroporation methods. It may help researchers learn which treatments are used in practice and what outcomes people experience.
LondonAges Any age - NCT04930432RecruitingPhase 1/Phase 2
MCLA-129 for advanced EGFR- and MET-positive lung and other cancers
This early-phase trial tests MCLA-129, an antibody that targets EGFR and MET, in people with advanced cancers that have specific lab “biomarker” results. It’s for patients whose cancer has grown after standard treatments or can’t take standard treatment, with the goal of shrinking tumors and improving symptoms.
BaodingAges 18 years+ - NCT04929899Recruiting
Test of a learning tool during leukemia maintenance
This study checks whether a tablet-based tool (called PeNAT) can be used by children during the usual maintenance treatment phase for ALL (a type of leukemia). It may help families and clinicians better support care at home or during follow-up by testing how well the tool works in real patients.
Los Angeles, CaliforniaAges 4–18 - NCT04931732Recruiting
Liquid blood test to diagnose brain glioma
This trial checks whether a special blood test can help identify glioma (a type of brain tumor) that is new or coming back. It may help doctors learn more about the tumor using blood, alongside the usual brain scans and planned surgery.
BronAges 18–90
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,648 recruiting oncology studies from the U.S. registry right now, out of 31,565 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.